A screening of a library of T7 phage-displayed peptide identifies E2F-4 as an etoposide-binding protein

Molecules

Volumn 16, Issue 5, 2011, Pages 4278-4294

  Takami, Mihoko ^a   Takakusagi, Yoichi ^a   Kuramochi, Kouji ^a   Tsukuda, Senko ^a   Aoki, Satoko ^a   Morohashi, Kengo ^a   Ohta, Keisuke ^a   Kobayashi, Susumu ^a   Sakaguchi, Kengo ^a   Sugawara, Fumio ^a  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

E2F 4; Etoposide (VP 16); Peptide; Surface plasmon resonance; T7 phage display; Transcription

Indexed keywords

CARRIER PROTEIN; DRUG DERIVATIVE; ETOPOSIDE; PEPTIDE; PEPTIDE LIBRARY; TRANSCRIPTION FACTOR E2F;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; BACTERIOPHAGE T7; BIOTINYLATION; CHEMISTRY; CHO CELL; CRICETULUS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HAMSTER; HUMAN; METABOLISM; MOLECULAR GENETICS; PROTEIN BINDING; REPORTER GENE; SEQUENCE ALIGNMENT; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

AMINO ACID SEQUENCE; ANIMALS; BACTERIOPHAGE T7; BIOTINYLATION; CARRIER PROTEINS; CHO CELLS; CRICETINAE; CRICETULUS; DRUG SCREENING ASSAYS, ANTITUMOR; E2F TRANSCRIPTION FACTORS; ETOPOSIDE; GENE EXPRESSION REGULATION; GENES, REPORTER; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PEPTIDES; PROTEIN BINDING; SEQUENCE ALIGNMENT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79957592711     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules16054278     Document Type: Article

References (28)

1. Keller-Juslen, C.; Kuhn, M.; Stahelin, H.; von Wartburg, A. Synthesis and antimitotic activity of glycosidic lignan derivatives related to podophyllotoxin. J. Med. Chem. 1971, 14, 936-940.
2. Baldwin, E.L.; Osheroff, N. Etoposide, topoisomerase II and cancer. Curr. Med. Chem. Anticancer Agents 2005, 5, 363-372.
3. Chiu, C.C.; Lin, C.H.; Fang, K. Etoposide (VP-16) sensitizes p53-deficient human non-small cell lung cancer cells to caspase-7-mediated apoptosis. Apoptosis 2005, 10, 643-650. (Pubitemid 40896669)
4. Burden, D.A.; Kingma, P.S.; Froelich-Ammon, S.J.; Bjornsti, M.A.; Patchan, M.W.; Thompson, R.B.; Osheroff, N. Topoisomerase II.etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. J. Biol. Chem. 1996, 271, 29238-29244. (Pubitemid 26382636)
5. Chen, G.L.; Yang, L.; Rowe, T.C.; Halligan, B.D.; Tewey, K.M.; Liu, L.F. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem. 1984, 259, 13560-13566. (Pubitemid 15221834)
6. Soues, S.; Wiltshire, M.; Smith, P.J. Differential sensitivity to etoposide (VP-16)-induced S phase delay in a panel of small-cell lung carcinoma cell lines with G1/S phase checkpoint dysfunction. Cancer Chemother. Pharmacol. 2001, 47, 133-140. (Pubitemid 32662318)
7. Davis, M.P.; Murthy, M.S.; Simon, J.; Wise, H., Minton, J.P. Successful management of small cell carcinoma of the bladder with cisplatin and etoposide. J. Urol. 1989, 142, 817. (Pubitemid 19226734)
8. Walther, P.J.; Williams, S.D.; Troner, M.; Greco, F.A.; Birch, R.; Einhorn, L.H. Phase II study of etoposide for carcinoma of the bladder: The Southeastern Cancer Study Group experience. Cancer Treat. Rep. 1986, 70, 1337-1338. (Pubitemid 17184303)
9. Morris, M.; Brader, K.R.; Burke, T.W.; Levenback, C.F.; Gershenson, D.M. A phase II study of prolonged oral etoposide in advanced or recurrent carcinoma of the cervix. Gynecol. Oncol. 1998, 70, 215-218. (Pubitemid 28430932)
10. Kredentser, D.C. Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix. Gynecol. Oncol. 1991, 43, 145-148.
11. Slayton, R.E.; Blessing, J.A.; Homesley, H.D. Phase II trial of etoposide in the management of advanced or recurrent non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. Cancer Treat. Rep. 1984, 68, 1513-1514. (Pubitemid 15187588)
12. Dubrez, L.; Goldwasser, F.; Genne, P.; Pommier, Y.; Solary, E. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia 1995, 9, 1013-1024.
13. Lee, Y.S.; Lee, E.K.; Han, I.O.; Park, S.H. Etoposide-induced Smad6 expression is required for the G1 to S phase transition of the cell cycle in CMT-93 mouse intestinal epithelial cells. Exp. Mol. Med. 2008, 40, 43-51.
14. Kurosu, T.; Takahashi, Y.; Fukuda, T.; Koyama, T.; Miki, T.; Miura, O. p38 MAP kinase plays a role in G2 checkpoint activation and inhibits apoptosis of human B cell lymphoma cells treated with etoposide. Apoptosis 2005, 10, 1111-1120. (Pubitemid 41285586)
15. Nakada, S.; Katsuki, Y.; Imoto, I.; Yokoyama, T.; Nagasawa, M.; Inazawa, J.; Mizutani, S. Early G2/M checkpoint failure as a molecular mechanism underlying etoposide-induced chromosomal aberrations. J. Clin. Invest. 2006, 116, 80-89. (Pubitemid 43121793)
16. Takakusagi, Y.; Takakusagi, K.; Sugawara, F.; Sakaguchi, K. Use of phage display technology for the determination of the targets for small-molecule therapeutics. Expert Opin. Drug Discov. 2010, 5, 361-389.
17. Homola, J. Surface plasmon resonance sensors for detection of chemical and biological species. Chem. Rev. 2008, 108, 462-493. (Pubitemid 351350388)
18. Komatsu, N.; Takeuchi, S.; Ikezoe, T.; Tasaka, T.; Hatta, Y.; Machida, H.; Williamson, I.K.; Bartram, C.R.; Koeffler, H.P.; Taguchi, H. Mutations of the E2F4 gene in hematological malignancies having microsatellite instability. Blood 2000, 95, 1509-1510. (Pubitemid 30099870)
19. Litovchick, L.; Sadasivam, S.; Florens, L.; Zhu, X.; Swanson, S.K.; Velmurugan, S.; Chen, R.; Washburn, M.P.; Liu, X.S.; DeCaprio, J.A. Evolutionarily conserved multisubunit RBL2/p130 and E2F4 protein complex represses human cell cycle-dependent genes in quiescence. Mol. Cell 2007, 26, 539-551. (Pubitemid 46779093)
20. Chang, W.Y.; Bryce, D.M.; D'Souza, S.J.; Dagnino, L. The DP-1 transcription factor is required for keratinocyte growth and epidermal stratification. J. Biol. Chem. 2004, 279, 51343-51353. (Pubitemid 40017881)
21. Maehara, K.; Yamakoshi, K.; Ohtani, N.; Kubo, Y.; Takahashi, A.; Arase, S.; Jones, N.; Hara, E. Reduction of total E2F/DP activity induces senescence-like cell cycle arrest in cancer cells lacking functional pRB and p53. J. Cell Biol. 2005, 168, 553-560. (Pubitemid 40271020)
22. Zheng, N.; Fraenkel, E.; Pabo, C.O.; Pavletich, N.P. Structural basis of DNA recognition by the heterodimeric cell cycle transcription factor E2F-DP. Genes Dev. 1999, 13, 666-674. (Pubitemid 29155973)
23. Matsubara, N.; Yoshitaka, T.; Matsuno, T.; Ikeda, M.; Isozaki, H.; Tanaka, N.; Shimizu, K. Multiple tumors and a novel E2F-4 mutation. A case report. Digestion 2000, 62, 213-216.
24. Takashima, H.; Matsumoto, Y.; Matsubara, N.; Shirakawa, Y.; Kawashima, R.; Tanino, M.; Ito, S.; Isozaki, H.; Ouchida, M.; Meltzer, S.J.; Shimizu, K.; Tanaka, N. Effect of naturally occurring E2F-4 alterations on transcriptional activation and proliferation in transfected cells. Lab. Invest. 2001, 81, 1565-1573. (Pubitemid 33064282)
25. Yoshitaka, T.; Matsubara, N.; Ikeda, M.; Tanino, M.; Hanafusa, H.; Tanaka, N.; Shimizu, K. Mutations of E2F-4 trinucleotide repeats in colorectal cancer with microsatellite instability. Biochem. Biophys. Res. Commun. 1996, 227, 553-557. (Pubitemid 26362841)
26. Smith, P.J.; Soues, S.; Gottlieb, T.; Falk, S.J.; Watson, J.V.; Osborne, R.J.; Bleehen, N.M. Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells. Br. J. Cancer 1994, 70, 914-921. (Pubitemid 24331086)
27. Takakusagi, Y.; Takakusagi, K.; Kuramochi, K.; Kobayashi, S.; Sugawara, F.; Sakaguchi, K. Identification of C10 biotinylated camptothecin (CPT-10-B) binding peptides using T7 phage display screen on a QCM device. Bioorg. Med. Chem. 2007, 15, 7590-7598. (Pubitemid 47575926)
28. Takakusagi, Y.; Kuroiwa, Y.; Sugawara, F.; Sakaguchi, K. Identification of a methotrexatebinding peptide from a T7 phage display screen using a QCM device. Bioorg. Med. Chem. 2008, 16, 7410-7414.